Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Nuvation Bio Inc NUVB

Healthcare Biotechnology
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug... see more

Current News (NYSE:NUVB)

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Business Wire 6 days ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 12, 2026

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Business Wire January 12, 2026

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Business Wire January 6, 2026

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

PR Newswire December 6, 2025

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Business Wire December 3, 2025

Nuvation Bio to Participate in Upcoming Investor Conferences

Business Wire November 26, 2025

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Business Wire November 3, 2025

Nuvation Bio to Participate in Upcoming Investor Conferences

Business Wire October 30, 2025
View More News ››

Opinion & Analysis (NYSE:NUVB)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSE:NUVB)

Sell buddy sell.Wow.

Otherwise LOSE-O your money with this stock today anyway
coolfooldumbguy - January 12, 2026

50% up today

https://finance.yahoo.com/news/nuvation-bio-inc-nuvb-buy-111705338.html
Form001 - November 19, 2025
View more Bullboard ››

Forsys Metals Corp

Forsys Metals Corp

Forsys Metals Corp. together with its subsidiaries, engages in the acquisition, exploration, and development of uranium ...
View More »

Podcasts